🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 18 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/10/2025 14,78 14,84 13,71 14,03 -3,11% 7,65% 1.194.000
06/10/2025 13,80 16,12 13,61 14,48 +8,46% 18,19% 2.368.600
03/10/2025 13,40 13,58 13,21 13,35 -0,15% 2,76% 1.368.200
02/10/2025 13,56 13,70 12,90 13,37 -0,82% 5,90% 725.900
01/10/2025 13,42 13,90 13,42 13,48 -0,88% 3,58% 493.200
30/09/2025 13,14 13,63 13,05 13,60 +2,10% 4,41% 1.645.900
29/09/2025 12,94 13,36 12,87 13,32 +3,74% 3,75% 752.500
26/09/2025 12,38 12,86 12,15 12,84 +3,80% 5,74% 622.300
25/09/2025 12,49 12,79 12,23 12,37 -1,12% 4,48% 673.500
24/09/2025 12,40 12,68 12,30 12,51 +0,97% 3,06% 455.100
23/09/2025 12,53 12,98 12,32 12,39 -1,04% 5,27% 1.414.400
22/09/2025 12,39 12,99 12,20 12,52 +1,05% 6,38% 920.000
19/09/2025 12,47 12,51 12,11 12,39 -0,40% 3,18% 1.760.900
18/09/2025 12,27 12,49 12,09 12,44 +3,41% 3,26% 598.600
17/09/2025 11,72 12,41 11,68 12,03 +2,38% 6,23% 808.000
16/09/2025 11,58 11,85 11,58 11,75 +1,47% 2,33% 566.600
15/09/2025 11,59 11,70 11,30 11,58 +0,52% 3,49% 585.400
12/09/2025 11,50 11,84 11,44 11,52 +0,17% 3,48% 711.200
11/09/2025 11,76 12,05 11,44 11,50 -1,88% 5,23% 735.000
10/09/2025 11,33 11,81 11,16 11,72 +3,53% 5,74% 890.300
09/09/2025 11,23 11,36 11,10 11,32 -1,05% 2,35% 557.300
08/09/2025 12,21 12,23 11,04 11,44 -6,15% 9,75% 1.286.300
05/09/2025 11,64 12,24 11,53 12,19 +5,45% 6,10% 1.103.100
04/09/2025 11,65 11,69 11,28 11,56 -0,69% 3,52% 1.151.200
03/09/2025 10,84 11,84 10,72 11,64 +7,68% 10,33% 1.116.000
02/09/2025 10,60 11,06 10,55 10,81 +2,08% 4,81% 535.000
29/08/2025 10,64 10,81 10,40 10,59 -0,19% 3,90% 548.300
28/08/2025 10,56 10,96 10,53 10,61 +0,47% 4,12% 633.100
27/08/2025 10,31 10,62 10,25 10,56 +1,73% 3,59% 517.600
26/08/2025 10,12 10,40 10,07 10,38 +2,27% 3,21% 548.400